2020, Number 4
Carcinoma basocelular de alto riesgo, respuesta al tratamiento combinado con HeberFeron y radioterapia superficial. Presentación de un caso
Language: Spanish
References: 13
Page: 569-575
PDF size: 365.25 Kb.
ABSTRACT
Introduction: basal cell carcinoma is a malignant tumor of cutaneous location and is the most frequent in humans, especially in the white race. When it appears in the periocular region it is considered to be of high risk due to the possibility of invasion into adjacent and underlying structures.Case presentation: male patient, skin phototype II, who came to the clinic because of the presence of a tumor lesion of 5x2.5cm in diameter, located in the left temple, involving the external angle of the eye. Clinical and histological diagnosis was made and treatment with HeberFeron was decided due to the location and size of the lesion. A first cycle of treatment was performed and a partial response was obtained with a reduction of the lesion to 2x2cm, and then a second cycle of treatment was decided. It was maintained as a stable disease, so treatment with superficial radiotherapy was indicated; it presented complete disease response, clinical and dermatoscopic.
Conclusion: HeberFeron therapy was effective in reducing the lesion and, combined with superficial radiotherapy, achieved a complete clinical response and excellent aesthetic results.
REFERENCES
Jiménez Barbán Y, Vega Pupo C, Vila Pinillo D, Fernández Ychaso G, Arias Núñez V, Bello Rivero I. Uso de HeberPAG en carcinoma basocelular periocular. Rev Cubana Oftalmol [Internet]. 2014 Jul-Sep [citado 18/03/2019];27(3):482-489. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-21762014000300014&lng=es
CECMED. Resumen de las características del producto. HeberFeron® (Interferón alfa 2b hu-rec + Interferón gamma hu-rec) [Internet]. La Habana: Centro para el Control Estatal de Medicamentos; 2017 [citado 18/03/2019]. Disponible en: https://www.cecmed.cu/sites/default/files/adjuntos/rcp/biologicos/rcp_heberferon_0.pdf
American Cáncer Society. Radioterapia para los cánceres de piel de células basales y de células escamosas. Atlanta: American Cáncer Society; 2016 [actualizado 17/05/2016; citado 19/03/2019]. Disponible en: https://www.cancer.org/es/cancer/cancer-de-piel-de-celulas-basales-y-escamosas/tratamiento/radioterapia.html
Eva Garagorri E, Luis Valdivia L, Bruno Ciriani B, José Chang J. Evaluación de la radioterapia superficial en el tratamiento del carcinoma basocelular en el servicio de dermatología del Hospital Central de la FAP. Dermatol Perú [Internet]. 2002 [citado 14/03/2019];12(3):190-97. Disponible en: http://sisbib.unmsm.edu.pe/bvrevistas/dermatologia/v12_n3/evaluacion.htm
Rojas Rondón I, Duncan Roberts Y, Gómez Cabrera CG, Ramírez García LK, Vigoa Aranguren L, Hernández Rodríguez R, et al. Administración del HeberFeron en el carcinoma basocelular palpebral a propósito de 2 casos. Bionatura [Internet]. 2016 [citado 14/03/2019];1(2):71-4. Disponible en: http://revistabionatura.com/heberferon.html